Cheorl-Ho Kim – författare

Pathophysiological Aspects of Proteases in Cancer provides a comprehensive overview of the multifaceted field of proteases in the cellular environment and focuses on the recently elucidated functions of complex proteolytic systems in physiology and pathophysiology. The book both gives insights on the general aspects of the role of proteases in cancer, their role as diagnostics and prognostics biomarkers, their impact on chemoresistance, and the future cutting-edge technologies like cocktail therapies and Cyber Knife technology. Given the breadth and depth of information covered in the respective contributions, the book will be immensely useful for researchers in oncology and working to identify targets for drug development.Multidisciplinary in scope, the book bridges the gap between fundamental and translational research, with applications in the biomedical and pharmaceutical industry, making it a thought-provoking read for basic and applied scientists engaged in biomedical research.Gives insight into the spectrum of proteases, protease inhibitors, and protease interactors involved at the cellular and molecular level in cancer developmentGives a comprehensive overview of the role of proteases in modulating cellular metabolism and chemoresistance to better understand how proteases play in early to the end point in cancer development and metastasisProvides a multidisciplinary approach demonstrating the biochemical and signal transduction mechanisms associated with dysregulation of proteases, leading to the manifestation of various diseasesHighlights the roles and regulation of different types of proteases, as well as their synthetic and endogenous inhibitorsBridges the gap between fundamental and translational research, with applications in the biomedical and pharmaceutical industry

Cholinergic Drugs for Alzheimer’s Disease: From Central Cholinergic Neurotransmission to Drug Therapies and Natural Products with Multitarget Actions addresses the urgent need for advanced resources in neuropharmacology. The first section presents mechanistic insights into cholinergic drugs, current hypotheses for Alzheimer’s Disease progression, neurotransmitter systems, receptor biology, and the evolution of acetylcholinesterase inhibitors, including hybrid and multi-target drugs. It also covers clinical status, neuromuscular blockers, non-adrenergic neurotransmitters, protein kinase inhibitors, inflammation modulation, NMDA antagonism, biomarkers, and AI-assisted drug discovery.The second section explores natural alkaloidal and non-alkaloidal compounds, molecular docking, SAR analysis, and daily consumable resources, with the third section investigating marine-derived AChE inhibitors, dual- and multi-target drug concepts, and emerging therapeutic compounds. This book equips the scientific community with a robust foundation for understanding and innovating in Alzheimer’s Disease therapy. By integrating molecular biology, pharmacology, and computational approaches, it empowers researchers and clinicians to address treatment challenges, optimize drug design, and leverage natural products for multifactorial intervention.Explores cholinesterase inhibitors for cognitive improvementSummarizes receptor mechanisms in cholinergic transmissionReviews marine and plant-derived AChE inhibitors for innovative treatmentsPresents emerging drug therapies and multitarget natural compounds for Alzheimer’s Disease

Carbohydrate antigens on glycoconjugates of mammalian cells play crucial roles in various biological processes and are epitopes recognized by the immune system, as glycobiology has hugely been progressed during the past two decades. The book focuses on sialic acid–based xenoantigenes. In pig to human xenotransplantation, exposure of pig organs to human blood results in hyper acute rejection (HAR), caused by differences in carbohydrate epitopes between human and pig vascular endothelia. Although Gal-antigen as major antigen was eliminated, the remaining non-Gal antigens are considered to be xenoantigens. Sialosyl-Tn or Hanganutziu-Deicher (HD), are non-Gal antigens specific to natural antibodies in human. To overcome rejection responses such as HAR, studies of genes involved in carbohydrate antigens, causing xenoantigenicity, are necessary. Knowledge of pig glycosyltransferases are also useful to apply to xenoantigen masking or identification of the xenoantigenic sialylglycan(s). In the first chapter the screening for pig glycosyltransferase genes for xenoantigens is presented. In the chapter II to IV the cloning, characterization, and investigation of the regulatory mechanism of the pig CMAH gene in NeuGc biosynthesis is shown. Lastly, the effects of an alteration of pig glycosylation patterns on human serum-mediated cytotoxicity, caused by human sialyltransferases including hST6GalNAc IV is presented.

Carbohydrate antigens on glycoconjugates of mammalian cells play crucial roles in various biological processes and are epitopes recognized by the immune system, as glycobiology has hugely been progressed during the past two decades. The book focuses on sialic acid–based xenoantigenes. In pig to human xenotransplantation, exposure of pig organs to human blood results in hyper acute rejection (HAR), caused by differences in carbohydrate epitopes between human and pig vascular endothelia. Although Gal-antigen as major antigen was eliminated, the remaining non-Gal antigens are considered to be xenoantigens. Sialosyl-Tn or Hanganutziu-Deicher (HD), are non-Gal antigens specific to natural antibodies in human. To overcome rejection responses such as HAR, studies of genes involved in carbohydrate antigens, causing xenoantigenicity, are necessary. Knowledge of pig glycosyltransferases are also useful to apply to xenoantigen masking or identification of the xenoantigenic sialylglycan(s). In the first chapter the screening for pig glycosyltransferase genes for xenoantigens is presented. In the chapter II to IV the cloning, characterization, and investigation of the regulatory mechanism of the pig CMAH gene in NeuGc biosynthesis is shown. Lastly, the effects of an alteration of pig glycosylation patterns on human serum-mediated cytotoxicity, caused by human sialyltransferases including hST6GalNAc IV is presented.

This book reviews recent progress in understanding of the signaling and biochemistry of GM3 ganglioside in eukaryotic cells.

This book reviews recent progress in understanding of the signaling and biochemistry of GM3 ganglioside in eukaryotic cells.

Cellular GSLs are associated with many biological functions such as cellular oncotransformation, phenotype change, neuronal or embryonic development, regulation of cell division, cell–cell interaction, cell attachment, adhesion, and motility, and intracellular signaling via protein–carbohydrate or carbohydrate–carbohydrate interactions.

Cellular GSLs are associated with many biological functions such as cellular oncotransformation, phenotype change, neuronal or embryonic development, regulation of cell division, cell–cell interaction, cell attachment, adhesion, and motility, and intracellular signaling via protein–carbohydrate or carbohydrate–carbohydrate interactions.

Ganglioside adsorption, disorders of ganglioside degradation, and the regulation of gangliosides are thoroughly discussed.

Ganglioside adsorption, disorders of ganglioside degradation, and the regulation of gangliosides are thoroughly discussed.

This book presents the latest knowledge and the most recent research results on glycobiology of innate immunology. Innate immunity is the crucial part of the immunological defense system that exerts their distinct functions through binding to certain functional glycoproteins. They play a role in various human diseases and also function against microbial invaders and self-associated molecular patterns. Co-regulated expression of glycan-binding is associated with many biological components such as cellular oncotransformation, phenotype change, neuronal or embryonic development, regulation of cell division, cell–cell interaction, cell attachment, adhesion, and motility, and intracellular signaling via protein–carbohydrate or carbohydrate–carbohydrate interactions.This book opens by providing the key background on glycans in innate immunity and its mechanisms behind the Dendritic cell interactions during infection and inflammation are examined in depth, and the concluding chapteris devoted to signaling tumor immunotherapy. Up-to-date information is then presented on all aspects of glycan structure-recognizing signaling. The book should assist in the further development of new strategies against emerging infectious agents and intractable diseases.

This book presents the latest knowledge and the most recent research results on glycobiology of innate immunology. Innate immunity is the crucial part of the immunological defense system that exerts their distinct functions through binding to certain functional glycoproteins. They play a role in various human diseases and also function against microbial invaders and self-associated molecular patterns. Co-regulated expression of glycan-binding is associated with many biological components such as cellular oncotransformation, phenotype change, neuronal or embryonic development, regulation of cell division, cell–cell interaction, cell attachment, adhesion, and motility, and intracellular signaling via protein–carbohydrate or carbohydrate–carbohydrate interactions.This book opens by providing the key background on glycans in innate immunity and its mechanisms behind the Dendritic cell interactions during infection and inflammation are examined in depth, and the concluding chapteris devoted to signaling tumor immunotherapy. Up-to-date information is then presented on all aspects of glycan structure-recognizing signaling. The book should assist in the further development of new strategies against emerging infectious agents and intractable diseases.

Modification or deletion of the specific gene locus for immune rejection on genome of donor animalsdisrupts the immunological recognition ligands of the donor organs, consequently preventing the immune rejection of the human recipient and xenograft rejection.